In vivo, PRGL493 treatment suppressed tumor growth in ZR-75-BQ xenografts (Figure 4H), but did not affect the body weight (Figure S4), highlighting the translational potential of targeting ACSL4 in BQ-high tumors and supporting the safety of PRGL493 at the administrated dose. This evidence concerns the gene ACSL4 and neoplasm.